{
  "schema": "https://data.sciveyor.com/schema",
  "version": 5,
  "id": "doi:10.1371/journal.pbio.1001848",
  "doi": "10.1371/journal.pbio.1001848",
  "externalIds": [
    "pii:PBIOLOGY-D-14-01082"
  ],
  "license": "This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.",
  "licenseUrl": "https://creativecommons.org/licenses/by/4.0/",
  "dataSource": "Public Library of Science",
  "dataSourceUrl": "https://data.sciveyor.com/source/plos",
  "dataSourceVersion": 1,
  "type": "article",
  "title": "Correction: Impairment of TrkB-PSD-95 Signaling in Angelman Syndrome",
  "authors": [
    {
      "name": "The PLOS Biology Staff"
    }
  ],
  "journal": "PLoS Biology",
  "date": "2014-04",
  "volume": "12",
  "number": "4",
  "pages": "e1001848",
  "tags": [
    "Type/Correction"
  ],
  "fullText": "JM wishes to declare the following competing interest, which should have been indicated in the research article. JM owned shares in Angelus Therapeutics. However, for clarification, no materials or support were received from this company, and no agreements were in place concerning the execution or publication of this work. In addition, a US patent application entitled “Long term potentiation with cyclic-GluR6 analogs” (US Patent Application #20120149646) has been filed by Brown University, with JM listed as co-inventor."
}